Earlier this year, a major announcement could be made today following the approval of the emergency use of an indigenous and foreign coronary vaccine in India. In fact, the Drug Controller General of India (DGCI) has called a press conference at 11 a.m. today for the Covid-19 vaccine, where a big announcement is being made.
– DD News (DDNewsLive) January 2, 2021
It was learned on Saturday that the expert committee had approved the use of India Biotech’s indigenous corona vaccine center. However, the final approval of the DG has not been received yet.
On Friday, the coronavirus vaccine ‘Covishield’, developed by the Serum Institute of India, including Oxford University and AstraZeneca, was approved for emergency use.
Union Health Minister Dr Harsh Vardhan also said on Saturday that about 30 million people across the country would be vaccinated against coronavirus free of cost in the first phase. Also, he said that no protocol will be compromised before approval.
Vaccine trials are currently underway in the country
Clinical trials of six coronary vaccines are currently underway in India. These include covishield and covacin. The Covishield Astroxy Vaccine, developed by AstraZeneca and the Serum Institute of India, Pune. Kovaxin is a desi vaccine developed in collaboration with the Indian Biotech of Indian Medical Research Council.
In addition to these two, Cadillac Health Care Limited of Ahmedabad is developing in collaboration with Zykovi-D Biotechnology Department. Also NVX-Covey 2373 is developing Serum Institute in collaboration with NovaMax. There are two more vaccines, one of which has been developed by Biological E Limited of Hyderabad in association with MIT, USA. The second HDT has been developed by Pune-based Genova Biopharmaceuticals Limited in collaboration with USA.